Clinical trials: Growth Hormone Disorder
Breast Cancer, Chemotherapy Effect
Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks
According to the latest data from the World Health Organization's International Agency for Research on Cancer (IARC) for 2020, breast cancer has been the most prevalent cancer with 2.26 million new cases.
- Trial name
- NCT05212454
- Testing
- Capecitabine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Metastatic Breast Cancer
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Hormone receptor positive breast cancer is the most common type of breast cancer, comprising 70-80% of all breast cancers. Endocrine therapy is the main type of initial treatment for patients with your type of breast cancer.
- Trial name
- NCT00759642
- Testing
- lapatinib
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of Kansas Medical Center
Constitutional Growth Delay, Nutrition Disorders
Nutrients and Hormones: Effects in Boys With Disordered Growth
The purpose of the study is to find out if patients with constitutional delay of growth have a mismatch between energy intake and utilization (as measured by doubly labeled water) and to compare the improvement in growth and…
- Conditions
- Constitutional Growth Delay, Nutrition Disorders, Growth Disorders
- Trial name
- NCT00139451
- Testing
- Pediasure, GH
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nemours Children's Clinic
Infertility
Growth Hormone to Improve the Clinical Outcome of Assisted Fertility in Young Patients With Decreased Ovarian Reserve
This study was a prospective randomized controlled trial. Patients aged <35 years with decreased clinical reserve function (AFC<5, Follicle stimulating hormone > 10miu/ml, Anti-mullerian hormone < 1.1μg/L) and receiving IVF/ICSI…
- Trial name
- NCT05585177
- Testing
- Growth hormone
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Nanjing University
Growth Hormone Deficiency, Endocrine System Diseases
A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
A 38-week dosing trial of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus placebo-control.
- Conditions
- Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
- Trial name
- foresiGHt (NCT04615273)
- Testing
- Lonapegsomatropin, Somatropin
- Where
- 113 sites in United States, Armenia and 22 more
- Volunteers
- 264 people
- Sponsor
- Ascendis Pharma Endocrinology Division A/S
Infertility, Infertility (IVF Patients)
Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization
The goal of this study is to evaluate the role of Somatropin and Dehydroepiandrosterone (DHEA) on ovarian reserve parameters and intracytoplasmic sperm injection (ICSI) outcome in poor ovarian responder.
- Trial name
- NCT07323329
- Testing
- Somatropin (4IU for 1 month) plus, folic acid 400 mcg per day., DHEA plus folic acid 400mcg per day, control group
- Where
- Egypt
- Volunteers
- 165 people
- Sponsor
- Beni-Suef University
Growth Hormone Deficiency
Reference Values for Body Composition Parameters and IGF-I in the Adult NordiNet® International Outcome Study
The treatment of Growth Hormone deficiency (GHD) patients with GH, often induce fluid retention; this effect is dose dependent and temporary. The symptoms are swelling of soft tissue and joint stiffness.
- Trial name
- NCT01120977
- Where
- Denmark
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Genetic Disorder, Achondroplasia
A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin
This study is conducted in Japan. The aim of the study is to evaluate the efficacy of somatropin (Norditropin®) on adult height (cm) in patients with achondroplasia / hypochondroplasia enrolled in the GH-1941 study (NCT01516229).
- Trial name
- NCT01435629
- Testing
- somatropin
- Where
- Japan
- Volunteers
- 81 people
- Sponsor
- Novo Nordisk A/S
Infertility, Female
Efficacy of Growth Hormone Supplementation With Gonadotrophins in IVF/ICSI for Poor Responders
The objective of this study is to assess the effectiveness of adjuvant growth hormone injection during controlled ovarian stimulation, in poor responder women undergoing intracytoplasmic sperm injection (ICSI) procedures.
- Trial name
- NCT03759301
- Testing
- Growth Hormones Somatropin Recombinant
- Where
- Egypt
- Volunteers
- 156 people
- Sponsor
- ClinAmygate
Traumatic Brain Injury
Growth Hormone or Sildenafil as Therapies for Fatigue in Mild- Traumatic-brain-injury (MTBI)
The overall goal is to determine whether perceptual or performance fatigue can be reduced in MTBI patients with and without growth hormone (GH) deficiency by treating them in a crossover fashion based upon GH status.
- Trial name
- NCT02114775
- Testing
- Growth Hormone, Sildenafil
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Advanced Solid Tumor, Gynecologic Cancer
A Study of PY314 in Subjects With Advanced Solid Tumors
This is an open-label, multicenter, first in human, Phase 1a/1b study of PY314 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to standard of care (including…
- Conditions
- Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer
- Trial name
- NCT04691375
- Testing
- PY314, Combination Therapy: PY314 + Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 86 people
- Sponsor
- Ikena Oncology
Metastatic Breast Cancer
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+…
- Trial name
- NCT06018337
- Testing
- DB-1303/BNT323, Capecitabine, Paclitaxel
- Where
- 258 sites in United States, Argentina and 15 more
- Volunteers
- 541 people
- Sponsor
- DualityBio Inc.
Hypopituitarism, Pituitary Tumors
Effect of 5 Years of GH Replacement on Atherosclerosis
Adult patients with hypopituitarism under adequate conventional hormone replacement therapy have reduced life expectancy due to excess vascular events (1-4).
- Conditions
- Hypopituitarism, Pituitary Tumors, Growth Hormone Deficiency
- Trial name
- 5yrGH (NCT00462475)
- Testing
- Recombinant Growth Hormone, Genotropin (Pfizer)
- Where
- Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Federico II University
Growth Hormone Deficiency, Small-for-gestational Age
Growth and Asymmetric diMethylArginine
Principal objective : Validation of a handy biochemical parameter, plasma concentration of Asymmetric DimethylArginine (ADMA), based on a recognize biochemical parameter, the dilation of the brachial artery, at ultrasound…
- Trial name
- GAMMA (NCT03422081)
- Testing
- arterial doppler ultrasound
- Where
- 2 sites in France
- Volunteers
- 23 people
- Sponsor
- University Hospital, Lille
Growth Hormone Deficiency
A Study of Zomacton in Children With Growth Hormone Deficiency
This trial is set up to compare Zomacton to Genotropin for the treatment of growth hormone deficiency in children. The children will be treated for 1 year.
- Trial name
- NCT00884000
- Testing
- Genotropin, Zomacton
- Where
- 43 sites in Hungary, India and 5 more
- Volunteers
- 165 people
- Sponsor
- Ferring Pharmaceuticals
Growth Hormone Disorder, Growth Hormone Deficiency in Children
An Observational Study on Treatment Compliance by Children Treated With Growth Hormone
This study is conducted in Europe. This observational study aims at evaluating compliance with growth hormone treatment in children and identifying factors influencing compliance.
- Trial name
- IMPACT (NCT01068639)
- Testing
- No treatment given
- Sponsor
- Novo Nordisk A/S
Growth Hormone-Deficiency
A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children
The purpose of this study is to support selection of an appropriate safe and efficacious dose for study in further development.
- Trial name
- NCT02092077
- Testing
- TV-1106, somatropin
- Where
- 34 sites in Belarus, Bulgaria and 11 more
- Volunteers
- 65 people
- Sponsor
- Teva Pharmaceutical Industries, Ltd.
Growth Disorders, Intrauterine Growth Retardation
Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation
To evaluate the effect of continuous and intermittent administration of Genotonorm on stature in short prepubertal children with intra-uterine growth retardation
- Trial name
- NCT01073605
- Testing
- Genotonorm
- Where
- 31 sites in France
- Volunteers
- 208 people
- Sponsor
- Pfizer
Metastatic Breast Cancer
A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
The purpose of this study is to evaluate the efficacy and safety of SKB264 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer who have previously failed endocrine therapy.
- Trial name
- NCT07071337
- Testing
- SKB264, Nab-paclitaxel, Paclitaxel
- Where
- 2 sites in China
- Volunteers
- 430 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Growth Hormone Disorder, Healthy
Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx®
This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (exposure of drug) and pharmacodynamics (effect) of NNC126-0083 compared to Norditropin® SimpleXx® and placebo…
- Trial name
- NCT01034202
- Testing
- NNC126-0083, Norditropin® SimpleXx®
- Where
- Denmark
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S